ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Sunflower Therapeutics Announces Exclusive Distribution Agreement with Alflow Scandinavia A/S

Customers in Denmark, Norway, Sweden, and Iceland Can Now Purchase the Daisy Petal™ Perfusion Bioreactor System

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.

“Expanding into Europe with a trusted and innovative partner like Alflow allows us to support a broader community of scientists and biomanufacturers,” said Dr. Kerry Love, CEO and co-founder of Sunflower Therapeutics. "Alflow’s team brings a deep technical knowledge that aligns with our ongoing product commercialization goals and our objective of making protein manufacturing more intuitive, cost-effective, and efficient. We’re excited to work with their team to bring our technology overseas to new markets.”

Sunflower’s innovative Daisy Petal™ is a breakthrough technology designed for high-efficiency protein production using an intuitive, single-use assembly. The system features a disposable stirred tank reactor with an integrated in-vessel cell retention device that enables continuous biomass feeding, fluid harvesting, and perfusion, which results in significantly higher space-time yields compared to traditional fed-batch fermentation.

“Partnering with Sunflower Therapeutics allows us to bring a truly novel bioreactor solution to the Nordic market,” said Jacob Rosenkrands, CEO of Alflow Scandinavia A/S. “We are committed to offering our customers solutions that make a measurable difference. The Daisy Petal system stands out by combining simplicity, scalability, and performance – and we look forward to supporting our customers in bringing it into practice.”

Sunflower’s bioprocessing software suite, compliant with Good Manufacturing Practices (GMP) for use in regulated biomanufacturing, includes HelianthOS™, Nursery™, and Harvest™. These tools enable walkaway automation of fermentation processes, easy development of process recipes with no coding, and the secure storage of process data generated by the Daisy Petal™ System. Together, these three elements provide a cohesive ecosystem that enables efficient and intuitive operations throughout an entire campaign.

To learn more about the Daisy Petal™, contact Alflow Scandinavia A/S at https://www.alflow.dk/.

About Sunflower Therapeutics

Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods and Contract Research Organization (CRO) services for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing.

About Alflow Scandinavia A/S

Alflow Scandinavia A/S is a Danish team of flow technology experts that delivers high-quality components, technical advice, and works in close collaboration with customers in the pharma, food, and single-use industries. With more than 25 years of experience, the company turns expertise into reliable solutions that create value, ensure safety – and deliver flow that makes a difference. Visit: www.alflow.dk.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.